107 related articles for article (PubMed ID: 21757969)
1. Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases.
Ozkan H; Demirbaş S; Ibiş M; Akbal E; Köklü S
Pancreatology; 2011; 11(3):295-300. PubMed ID: 21757969
[TBL] [Abstract][Full Text] [Related]
2. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases.
Ozkan H; Akar T; Köklü S; Coban S
Pancreatology; 2006; 6(4):268-72. PubMed ID: 16636598
[TBL] [Abstract][Full Text] [Related]
3. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
5. Serum testosterone:dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer.
Robles-Díaz G; Díaz-Sánchez V; Fernández-del Castillo C; Morales M; Aceves G; Galván E; Altamirano A
Am J Gastroenterol; 1991 May; 86(5):591-4. PubMed ID: 2028950
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer.
Mohamed AA; Soliman H; Ismail M; Ziada D; Farid TM; Aref AM; Al Daly ME; Abd Elmageed ZY
Pancreatology; 2015; 15(1):34-9. PubMed ID: 25464937
[TBL] [Abstract][Full Text] [Related]
7. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
Yamaguchi K; Nakamura M; Shirahane K; Konomi H; Torata N; Hamasaki N; Kawakita M; Tanaka M
Dig Liver Dis; 2005 Mar; 37(3):190-4. PubMed ID: 15888284
[TBL] [Abstract][Full Text] [Related]
8. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
10. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
[TBL] [Abstract][Full Text] [Related]
11. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
13. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Tumour Biol; 1994; 15(1):52-60. PubMed ID: 8146530
[TBL] [Abstract][Full Text] [Related]
15. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
[TBL] [Abstract][Full Text] [Related]
16. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
[TBL] [Abstract][Full Text] [Related]
17. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
19. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
20. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]